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Abstract
Objective—The effects of coronary perivascular adipose tissue (PVAT) on vasomotor tone are 
influenced by an obese phenotype and are distinct from other adipose tissue depots. The purpose 
of this investigation was to examine the effects of lean and obese coronary PVAT on end-effector 
mechanisms of coronary vasodilation and to identify potential factors involved.
Approach and Results—Hematoxylin and eosin staining revealed similarities in coronary 
perivascular adipocyte size between lean and obese Ossabaw swine. Isometric tension studies of 
isolated coronary arteries from Ossabaw swine revealed that factors derived from lean and obese 
coronary PVAT attenuated vasodilation to adenosine. Lean coronary PVAT inhibited KCa and 
KV7, but not KATP channel mediated dilation in lean arteries. In the absence of PVAT, 
vasodilation to KCa and KV7 channel activation was impaired in obese arteries relative to lean 
arteries. Obese PVAT had no effect on KCa or KV7 channel mediated dilation in obese arteries. In 
contrast, obese PVAT inhibited KATP channel mediated dilation in both lean and obese arteries. 
The differential effects of obese versus lean PVAT were not associated with changes in either 
coronary KV7 or KATP channel expression. Incubation with calpastatin attenuated coronary 
vasodilation to adenosine in lean but not obese arteries.
Conclusions—These findings indicate that lean and obese coronary PVAT attenuates 
vasodilation via inhibitory effects on vascular smooth muscle K+ channels and that alterations in 
specific factors such as calpastatin are capable of contributing to the initiation and/or progression 
of smooth muscle dysfunction in obesity.
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Introduction
Perivascular adipose tissue (PVAT) surrounds large arteries throughout the body and is 
capable of producing adipokines that act directly upon the adjacent vasculature.1;2 PVAT-
derived factors have been shown to stimulate chemotaxis, inflammation, and endothelial 
dysfunction, thereby implicating local PVAT signaling in the initiation and progression of 
vascular disease.3-8 Data from recent studies investigating vascular responses to PVAT-
derived factors suggest that the endothelial and smooth muscle effects of these substances 
are highly dependent on anatomic location of the adipose/vascular depot and the underlying 
disease state of the subjects from which the tissues were obtained.2 Such discrepant 
phenotypic effects of PVAT are not surprising given marked differences in protein 
expression and secretion profiles of adipose tissue depots from lean versus obese 
subjects.9-15 However, current understanding of how these alterations influence mechanisms 
of vascular function remains limited.
Differences in the vascular effects of PVAT-derived factors are evident when comparing 
peripheral (non-cardiac) versus coronary-cardiac PVAT. In particular, aortic,16;17 
mesenteric,18;19 and internal thoracic artery20;21 PVAT have been shown to significantly 
diminish contractile responses to a variety of agonists. This vasodilator or “anti-contractile” 
effect is attributed to production of adipose-derived relaxing factor(s) (ADRF(s)) that 
promote endothelial dependent and/or independent vasodilation via activation of voltage-
dependent KV7 channels,18 BKCa channels,21;22 and Kir channels.23 In contrast, factors 
released from coronary PVAT have been shown to attenuate endothelial-dependent 
dilation5;7 and potentiate coronary artery contractions.12 These deleterious effects of 
coronary PVAT are augmented in the setting of obesity and are directly associated with 
marked alterations in the coronary PVAT proteome and the functional expression of 
coronary K+ and Ca2+ channels.12;24;25 Specifically, our laboratory has recently 
demonstrated that the endogenous calpain inhibitor calpastatin26;27 is significantly elevated 
in the secreted protein expression profile of obese coronary PVAT and is sufficient to dose-
dependently augment coronary artery contractions in the absence of PVAT.12 Obesity has 
also been found to diminish the contribution of end-effector K+ channels to coronary 
vasodilator responses.28 These channels include voltage-dependent (KV), Ca2+-activated 
(KCa), and ATP-sensitive (KATP) channels, which regulate smooth muscle membrane 
potential and participate in the regulation of coronary vascular resistance.29 However, the 
extent to which coronary PVAT-derived factors modulate the role of these channels has not 
been investigated.
Accordingly, the purpose of this investigation was to delineate the effects of lean and obese 
coronary PVAT on end-effector mechanisms of coronary vasodilation and to identify 
potential PVAT-derived factors involved. Studies were specifically designed to test the 
hypothesis that lean and obese PVAT differentially attenuate KCa, KV, and KATP channel 
mediated vasodilation in the coronary circulation and that calpastatin contributes to these 
effects. Findings from this investigation add to growing evidence supporting a role for 
PVAT in the pathogenesis of vascular dysfunction in obesity-induced coronary disease.
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Materials and Methods
Materials and methods are available in the online-only data supplement.
Results
Phenotype of Lean and Obese Ossabaw Swine
Compared to their lean counterparts, obese swine exhibited significant increases in body 
weight, fasting glucose, total cholesterol, and triglycerides (Table 1). Histopathological 
analyses to examine the morphology of perivascular adipocytes were performed on sections 
of coronary arteries with the adjacent PVAT intact. Hematoxylin and eosin staining revealed 
apparent similarities in perivascular adipocyte size between lean (Figure 1A) and obese 
(Figure 1B) swine. Specifically, adipocyte diameter averaged 70 ± 1 μm in lean and 67 ± 2 
μm in obese swine (P = 0.24). These values are consistent with measures of coronary 
perivascular adipocyte diameter (Figure 1C, average = 66 ± 2 μm, n =2) from human 
subjects with evidence of coronary artery disease (Figure 1F). Verhoeff-van Gieson elastin 
stain demonstrated the presence of atheroma formation in obese (Figure 1E) compared to 
lean (Figure 1D) swine. These data are consistent with findings from other studies from our 
investigative team which documented ~15-20% stenosis of major coronary arteries (using 
intravascular ultrasound) in obese Ossabaw swine.30-32 Immunostaining for CD163, a 
marker for cells of the monocyte/macrophage lineage,33 revealed prominent staining in the 
medial layer of obese arteries (Figure 1I) with only modest staining evident in lean arteries 
(Figure 1H) relative to isotype control (Figure 1G). These findings are consistent with prior 
reports of inflammation in coronary arteries from obese swine.34
Lean and Obese PVAT Attenuate Coronary Vasodilation
To initially examine the effects of PVAT on vasodilation, coronary arteries cleaned of 
surrounding PVAT from lean and obese swine were incubated with or without a known 
quantity of coronary PVAT (0.3 g) from the same animal for 30 min (Figure II in the 
online-only supplement). Arteries were then pre-constricted with the thromboxane A2 
mimetic U46619 (1 μM). Active tension development of control arteries to U46619 (1 μM) 
in the absence of PVAT averaged 9.01 ± 0.41 g in lean and 10.20 ± 0.61 g in obese arteries 
(P = 0.09). In arteries treated with PVAT, active tension development averaged 9.61 ± 0.42 
g in lean and 9.88 ± 0.53 g in obese arteries (P = 0.68). Vasodilation to adenosine (30 μM) 
was reduced ~25% in obese (Figure 2B) compared to lean (Figure 2A) arteries in the 
absence of PVAT (P < 0.001). The presence of PVAT significantly attenuated adenosine 
relaxation at concentrations >3 μM in arteries from both lean and obese swine. Although 
maximal responses to adenosine were lower in obese arteries, the overall degree of PVAT 
inhibition on maximal adenosine-induced dilation (30 μM) was similar in lean (~31%) and 
obese (~32%) arteries (Figure 2A vs. Figure 2B). Preconstriction with KCl (60 mM), which 
averaged 7.19 ± 0.22 g in lean and 8.27 ± 0.90 g in obese arteries (P = 0.36), essentially 
abolished dilation to adenosine in both lean and obese arteries. Additional experiments in 
endothelium denuded coronary arteries demonstrated that adenosine-induced dilation was 
unaffected by removal of the endothelium in both control (P = 0.94) and PVAT treated (P = 
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0.99) arteries. Denudation was confirmed in these studies by <15% relaxation to bradykinin 
(1μM).
Lean Coronary PVAT Inhibits KCa and KV7 Channels
The contribution of KCa channels to coronary vasodilation in lean and obese hearts was 
examined by comparing responses to the KCa channel agonist NS1619 (1 μM – 30 μM). 
Overall responses to NS-1619 (30 μM) were reduced ~30% in obese compared to lean 
control arteries in the absence of PVAT (P = 0.01; Figure 3A vs. Figure 3B). Compared to 
control responses, the addition of PVAT attenuated dilator responses to the NS-1619 (30 
μM) by ~30% in lean arteries (P < 0.001; Figure 3A). In contrast, NS-1619 mediated 
dilation was unaffected by the addition of PVAT in obese arteries (P = 0.90; Figure 3B).
To investigate the role of KV7 channels in coronary vasodilation, responses to the KV7 
channel agonist L-364,373 (10 nM – 10 μM) were examined in lean and obese arteries. 
Dilation to L-364,373 was significantly attenuated at doses >3 μM in obese compared to 
lean control arteries in the absence of PVAT (P < 0.05; Figure 3C vs. Figure 3D). The 
presence of PVAT attenuated L-364,373 mediated dilation (10 μM) by ~20% in lean arteries 
(P = 0.02; Figure 3C) but had no effect in obese arteries (P = 0.98; Figure 3D). Western 
blot analyses of Kv7 channel (KCNQ1) protein indicated that the abundance of KCNQ1 was 
not significantly different in lean versus obese coronary arteries (P = 0.11; Figure 4A and 
4C). Abundance of β-actin was not significantly different in lean versus obese arteries (P = 
0.91), indicating equal protein loading between samples.
Obese coronary PVAT Inhibits KATP Channels
Studies to investigate the effect of coronary PVAT on KATP channel mediated dilation were 
performed by comparing responses to the KATP channel agonist cromakalim (30 nM – 1 
μM) in lean and obese arteries. Control responses to cromakalim (1 μM) were not 
significantly different in lean versus obese arteries in the absence of PVAT (P = 0.90; 
Figure 3E and 3F). The presence of coronary PVAT from the same animal had no effect on 
dilation to cromakalim (1 μM) in lean arteries (P = 0.57; Figure 3E). In contrast, PVAT 
significantly attenuated dilation to cromakalim in obese arteries (P = 0.02; Figure 3F). 
Western blot analyses show that abundance of KATP channel pore forming unit (Kir 6.1) 
protein was not different in obese compared to lean arteries (P = 0.40; Figure 4B and 4D). 
Abundance of β-actin was not significantly different in lean versus obese arteries (P = 0.34), 
indicating equal protein loading between samples.
Differential Effects of Lean versus Obese Coronary PVAT
In order to evaluate the specific effects of lean versus obese PVAT on K+ channel function, 
independent of differences in coronary artery responsiveness, control coronary arteries 
(cleaned of PVAT) from lean swine were incubated with known quantities of PVAT (0.3 g) 
from either lean or obese swine sacrificed on the same day. In contrast to the inhibitory 
effects of lean PVAT, obese PVAT had no effect on relaxation to NS-1619 (30 μM) or 
L-364,373 (10 μM) in lean arteries (P = 0.40; Figure 5A and P = 0.10; Figure 5B). 
Alternatively, obese PVAT significantly attenuated relaxation to cromakalim (1 μM) (P < 
0.001; Figure 5C) while lean PVAT had no effect (P = 0.57).
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Based on previous findings,12 additional proof-of-principle studies were performed to 
investigate the effects of calpastatin (10 μM) on coronary vasodilation. Incubation with 
calpastatin significantly attenuated vasodilation to adenosine (from 3 μM to 10 μM) in lean 
arteries cleaned of PVAT (P = 0.001; Figure 6A). In contrast, exposure to calpastatin had 
no effect on adenosine dilation in obese arteries cleaned of PVAT (P = 0.30; Figure 6B).
Discussion
This investigation was designed to delineate the effects of lean and obese coronary PVAT 
on end-effector mechanisms of coronary vasodilation and to identify potential factors 
involved. The major new findings of this study are: (1) diameters of adipocytes in epicardial 
coronary PVAT are similar in lean and obese swine (2) factors derived from lean and obese 
coronary PVAT attenuate vasodilation in response to adenosine; (3) lean coronary PVAT 
inhibits KCa and KV7 channel mediated dilation but has no effect on KATP channel mediated 
dilation in lean arteries; (4) coronary vasodilation to KCa and KV7 channel activation is 
impaired in obese relative to lean arteries in the absence of PVAT; (5) obese PVAT has no 
effect on KCa or KV7 channel activation in obese arteries; (6) obese PVAT inhibits KATP 
channel mediated vasodilation in both lean and obese coronary arteries; (7) calpastatin 
attenuates coronary vasodilation to adenosine in lean but not obese arteries. These findings 
provide novel evidence that lean and obese PVAT-derived factors attenuate coronary 
vasodilation via differential inhibition of K+ channels and implicate a mechanistic link 
between alterations in PVAT-derived factors, such as calpastatin, and diminished functional 
expression of coronary K+ channels in the setting of obesity.
Although the ability of PVAT to produce transferrable factors that influence the vasculature 
is well established, current understanding regarding the nature of this effect in specific 
adipose tissue depots remains rather limited. While the majority of studies on peripheral 
(non-cardiac) PVAT support the production of ADRF(s) and an overall “anti-contractile” 
effect,17-22;35-38 recent data indicate that coronary PVAT is unique relative to these other 
adipose depots both in its expression profile and effects on the vasculature.6;10;12 In 
particular, factors derived from coronary PVAT have been found to attenuate endothelial-
dependent dilation and potentiate coronary artery contractions, especially in the setting of 
obesity.5-7;12 Other studies in lean or hypercholesterolemic swine show little/no anti-
contractile effect of coronary PVAT in response to endothelin-1, angiotensin II, or the 
thromboxane A2 mimetic U46619.6;39;40 Results from the present study further support the 
distinct vascular effects of coronary PVAT in that lean and obese coronary PVAT 
significantly attenuate coronary vasodilator responses to adenosine. This impaired dilator 
response is directly related to effects of PVAT-derived factors on smooth muscle K+ 
channels, as adenosine-induced dilation was unaffected by endothelial denudation and was 
essentially abolished by pre-constriction with KCl (Figure 2A and 2B). Inhibitory effects of 
PVAT on K+ channels have significant (patho)physiologic implications as prior studies have 
clearly demonstrated the contribution of KV and KATP channels to the regulation of 
coronary microvascular tone29;41 and KCa channels in endothelial-dependent dilation.42;43
The present findings provide novel evidence that lean and obese PVAT have distinct 
inhibitory effects on specific K+ channel subtypes in lean and obese coronary arteries. 
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Specifically, factors derived from lean coronary PVAT impair KCa and KV7 channel 
mediated dilation, while factors derived from obese coronary PVAT attenuate KATP channel 
mediated dilation (Figure 3). The lack of effect of obese coronary PVAT on KCa and KV7 
channels was observed in both obese (Figure 3) and lean (Figure 5) coronary arteries and is 
thus not related to intrinsic differences in smooth muscle phenotype of lean versus obese 
swine. Therefore, the “cross-over” studies in which lean arteries (i.e. with normal vascular 
smooth muscle function) were incubated with lean and obese PVAT, strongly support that 
lean and obese PVAT-derived factors differentially affect KCa, KV7, and KATP channels. 
This distinction is important as we found that coronary vasodilation in response to KCa and 
KV7 channel agonists is attenuated in obese relative to lean arteries in the absence of PVAT 
(Figure 3). These data are consistent with prior work from our laboratory and others which 
demonstrated the functional down-regulation of BKCa and KV channels in the coronary 
circulation24;25;44-46 and suggest the potential for PVAT-derived factors to contribute to the 
initiation and progression of coronary vascular dysfunction in the setting of obesity.
There are several potential mechanisms that could contribute to the effects of PVAT-derived 
factors on coronary K+ channels. In particular, it does not appear that differences in K+ 
channel expression levels are responsible for the divergent effects of PVAT, as Western 
analyses revealed similar levels of KV7 (KCNQ1) and KATP (Kir6.1) channels in coronary 
arteries of lean and obese swine (Figure 4). Previous studies from our group also found 
augmented expression of BKCa channel subunits in coronary arteries of obese swine.25 
However, it is possible that expression of other channel subtypes and/or subunits could be 
altered in the setting of obesity. The potential for direct effects of PVAT-derived factors on 
specific coronary K+ channels is supported by prior evidence that NS-1619, L-364,373, and 
cromakalim directly open KCa, KV, and KATP channels (i.e. without activating 
transmembrane signaling pathways), as these agonists have been shown to bind to sites on 
channel subunits and increase the open probability of excised membrane patches.47-49 
Additionally, cellular signaling pathways also influence the response of these K+ channels to 
their respective agonists. For example, ischemic stimuli and Rho kinase signaling influence 
the response of KCa channels to NS-1619, 50;51 while the effects of L-364,373 on KV7 
channels may intersect with ERK signaling52 and PKC alters the KATP channel response to 
cromakalim.53 Therefore, it is possible that cellular signaling, including post-translational 
modifications such as phosphorylation, influences the response of vascular smooth muscle 
K+ channel activation in the presence of PVAT.54 Such effects are in line with previous 
studies from our laboratory which demonstrated that coronary PVAT influences both PKC 
and Rho kinase signaling.6;12 Whether coronary PVAT-derived factors interact with K+ 
channels directly and/or influence their function indirectly through intracellular signaling 
pathways warrants further investigation.
Identification of the precise factors responsible for the vascular effects of coronary PVAT 
remains a daunting task. Recent studies by the Weintraub laboratory have established that 
adipocytes from human coronary PVAT have a distinct phenotype and exhibit elevated 
expression of pro-inflammatory genes and genes associated with angiogenesis, coagulation, 
and vascular morphology.9;10;55;56 Evidence of macrophage infiltration (Figure 1I) and 
atheroma formation (Figure 1E) in obese arteries support a potential role for inflammatory 
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cross-talk between PVAT and the artery wall in the pathogenesis of atherosclerosis. A 
previous global proteomic assessment revealed the up-regulation of proteins associated with 
cellular growth, proliferation, and movement in obese versus lean coronary PVAT from 
swine.12 These differences appear to be independent of gross changes in morphology, as 
similarities in adipocyte diameter were found between lean and obese PVAT (Figure 1A 
and 1B). Of particular interest is the endogenous calpain inhibitor, calpastatin, which we 
have shown to be significantly elevated in supernatant of obese coronary PVAT and to dose-
dependently augment coronary artery contractions.12 Findings from the current investigation 
further support that calpastatin is capable of mimicking the effects of coronary PVAT in that 
it acts to impair smooth muscle dilation in response to adenosine in lean coronary arteries 
(Figure 6A). The loss of this effect in obese coronary arteries (Figure 6B) is consistent with 
the lack of effect of obese PVAT on KCa and KV7 channel mediated dilation in obese 
arteries (Figure 3B and 3D), and suggests that chronic local exposure of the coronary 
circulation to factors such as calpastatin could contribute to the impairment of smooth 
muscle function in the setting of obesity.
It is important to recognize that although a differential effect of lean versus obese PVAT on 
vascular function was demonstrated in lean, healthy arteries, the effect of lean PVAT on 
obese arteries was not examined in this investigation. Additionally, findings of the present 
study were produced following short-term (~30 min) exposure to PVAT ex vivo. Thus, a 
critical question remains as to whether chronic exposure of the coronary vasculature to the 
PVAT milieu directly contributes to the altered functional expression of K+ channels in the 
setting of obesity. We propose that as the severity of obesity and other cardiovascular risk 
factors (insulin resistance, hypercholesterolemia, hypertension) progresses, changes in the 
secretion profile of coronary PVAT adversely influences the function and expression of 
coronary ion channels. However, the extent to which phenotypic alterations in coronary 
PVAT causally contribute to mechanistic alterations in the obese coronary circulation merits 
further study.
In summary, the current findings demonstrate that although coronary perivascular 
adipocytes from lean and obese swine share similar morphology, lean and obese PVAT-
derived factors impair vasodilation via differential inhibition of vascular smooth muscle K+ 
channels. Specifically, our data are the first to demonstrate that lean coronary PVAT 
attenuates KCa and KV7 channel mediated dilation, while obese coronary PVAT impairs 
KATP channel mediated dilation. These results further support the paradigm of distinct 
“outside to inside” signaling influences of coronary PVAT and that alterations in specific 
factors such as calpastatin are capable of contributing to the initiation and/or progression of 
smooth muscle dysfunction in the setting of obesity.
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Significance
Coronary perivascular adipose tissue (PVAT) normally surrounds the major coronary 
arteries of the heart. Evidence is mounting to support the potential for factors derived 
from coronary PVAT to influence the pathogenesis of coronary vascular disease. In 
particular, recent studies indicate that coronary PVAT-derived factors initiate/potentiate 
contraction of vascular smooth muscle, a property distinct from other adipose tissue 
depots, and that this effect is significantly augmented in the setting of obesity. However, 
the effects of coronary PVAT on vasodilation have not been clearly defined. Results from 
this investigation indicate that coronary PVAT attenuates dilation via inhibitory effects 
on vascular K+ channels and that the mechanisms and factors involved in mediating these 
effects are markedly altered in the setting of obesity. These findings provide new insights 
into the unique vasoactive properties of coronary PVAT and the potential role of PVAT-
derived factors in obesity-induced coronary disease.
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Figure 1. 
Representative images of immunohistochemical analyses of coronary arteries and associated 
PVAT obtained from human (n=2), and lean and obese swine (n=4, each group). 
Hematoxylin and eosin-stained sections (10X) illustrated similarities in perivascular 
adipocyte morphology between humans and swine (A-C). Verhoeff-van Gieson stained 
sections (4X) showed evidence of atheroma formation in human (F) and obese (E) 
compared to lean (D) arteries. CD163 staining (10X) indicated a marked increase in 
macrophages in obese (I, arrows) compared to lean (H) arteries relative to isotype control 
(G).
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Figure 2. 
Coronary PVAT attenuates adenosine induced vasodilation. In control arteries cleaned of 
PVAT (n=6 each group), maximal vasodilation to adenosine was reduced ~25% in lean (A) 
compared to obese (B) arteries. The presence of PVAT from the same animal (n=6 each 
group) impaired dilation to a similar extent and constriction with KCl (n=3 each group) 
abolished adenosine dilation in lean and obese arteries. *P<0.05, PVAT vs. control. 
†P<0.001, lean vs. obese control.
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Figure 3. 
Effect of coronary PVAT on K+ channel mediated dilation is altered in obesity. Arteries 
were incubated in the absence (control) or presence of PVAT from the same animal. PVAT 
attenuated vasodilation to the KCa channel agonist NS-1619 in lean (A) but not obese (B) 
arteries. Dilation to the KV7 channel agonist L-364,373 was reduced in the presence of 
PVAT in lean (C) but not obese (D) arteries. In the absence of PVAT, dilation to NS-1619 
and L-364,373 was impaired in obese (B, D) relative to lean (A, C) arteries. KATP channel 
mediated dilation to cromakalim was unaffected by PVAT in lean (E) arteries but was 
Noblet et al. Page 15
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
impaired by PVAT in obese (F) arteries. *P<0.05, PVAT vs. control. †P<0.05, lean vs. 
obese control.
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Figure 4. 
Western blot analysis of coronary artery KCNQ1 and Kir6.1 channel expression. 
Representative blots of KCNQ1 (A) and Kir6.1 (B) channel expression in lean and obese 
arteries. Expression levels of both KCNQ1 (C) and Kir6.1 (D) were unaffected by an obese 
phenotype (P=0.11 and P=0.40, respectively). Average data (n=3 for each group) are 
expressed as % protein observed in lean swine.
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Figure 5. 
Effects of lean versus obese PVAT on coronary K+ channel mediated dilation in lean 
arteries. For comparison purposes, lean control and lean PVAT responses are re-plotted 
from Figure 2A, 2C and 2E. Obese PVAT had no effect on vasodilation of lean arteries to 
the KCa channel agonist NS-1619 (n=4 [A]) or the KV7 channel agonist L-364,373 (n=3 
[B]). Dilation of lean arteries to the KATP channel agonist cromakalim was attenuated by 
obese but not lean PVAT (n=3 [C]). *P<0.05 lean PVAT vs. control. †P<0.05, obese PVAT 
vs. control.
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Figure 6. 
Effect of calpastatin on coronary artery vasodilation to adenosine. Incubation with 
calpastatin (10 μM) attenuated adenosine dilation in lean (n=5 each group [A]) but not obese 
(n=5 [B]) arteries. *P<0.05 vs. control.
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TABLE 1
Phenotypic Characteristics of Lean and Obese Ossabaw Swine
Lean Obese
Body weight (kg) 62 ± 6 100 ± 5*
Heart weight (g) 182 ± 16 222 ± 15
Mean arterial pressure (mmHg) 102 ± 9 107 ± 5
Glucose (mg/dL) 154 ± 14 232 ± 21*
Insulin (μU/mL) 12 ± 1 14 ± 3
Total cholesterol (mg/dL) 74 ± 4 340 ± 61*
Triglycerides (mg/dL) 46 ± 5 78 ± 14*
Values are mean ± SE for a subset of lean (n=10) and obese (n=10) swine.
*
P<0.05 vs. lean
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